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Abstract
Purpose of Review This review will present the inflammatory contracted bladder as a clinical entity and will address its
pathophysiology, diagnosis and treatment.
Recent Findings The inflammatory contracted bladder is relevant since it is not a recognised urological condition and it can be
found in several affections to the urinary tract. Its medical management depends on its aetiology and severity.
Summary The inflammatory contracted bladder (ICB) is an ambiguous term that is used to describe the morphology of the inflamed
bladder with a reduced volumetric capacity and compliance. This condition is found in some urological pathologies such as bladder
outlet obstruction, infections, drug toxicity, radiation cystitis and other inflammatory diseases like interstitial cystitis, malacoplakia and
eosinophilic cystitis. This entity is usually presented at the end stage of disease and represents an irreversible damage to the urinary tract.
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Introduction
The term inflammatory contracted bladder (ICB) is included
in a diverse spectrum of urological diseases that affects the
function of the bladder, its volumetric capacity and compli-
ance; this condition could also cause deterioration of the upper
urinary tract and renal impairment. The presentation of the
ICB involves a wide range of storage and voiding symptoms.
There is considerable ambiguity about the aetiology, morphol-
ogy and clinical significance of the contracted bladder; how-
ever, it is important to assess and treat this condition because
of the potential irreversible damage to the urinary tract.
Background
Recent descriptions of the functional abnormalities of the
bladder were initially described in the French literature in
1897 by Jean Casimir Félix Guyon [1]. During 1917 in
San Francisco, Krotoszyner postulated the clinical diag-
nosis of the contracted bladder and reported some cysto-
scopic characteristics of this condition. He stated that the
underlying causes of the contracted bladder may share a
similar disordered physiological process; however, it may
occur on the basis of a variety of vesical and extravesical
factors [2]. A volumetric capacity of less than 50 mL was
used as a reference.
The current standardisation of terminology of lower uri-
nary tract function reported by the sub-committee of the
International Continence Society, does not present the ICB
as an associated condition with lower urinary tract dysfunction
and urodynamic studies [3••]. This review presents a compre-
hensive analysis of the ICB according to the database findings
in the medical literature.
Pathophysiology
Several theories could be postulated in the pathophysiology of
the ICB. It is important to recognise that it is challenging to
determine specific tissue changes because this condition
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involves several pathological pathways in the development of
bladder dysfunction.
Urothelium
Alterations on the urothelial cells like the loss of tight junc-
tions ormodifications on themembrane cell structure are com-
promised by several conditions such as infections, inflamma-
tion, chemical exposure or radiation. The impairment of the
epithelial impermeability could manifest with elevation of in-
flammatory and fibrosis markers together with reduced blad-
der capacity and ICB [4, 5•].
Stroma
The main elements of the bladder stroma are collagen and
elastin surrounded by fibroblasts and a matrix of proteogly-
cans. The normal bladder responds well to changes in bladder
volume and pressure. Bladder collagen and elastin are related
to tissue compliance; there are several collagen isoforms, type
I and III are the most important. An increased type III to I ratio
has been reported in the non-compliant bladder tissue where
there is an increased expression of type III collagen mRNA
[6]. Elastin gene suppression has also been reported in the
non-compliant human bladder [7].
Hypertrophy
Molecular alterations on the signalling pathways have been
documented on animal models with bladder dysfunction.
Decompensated bladders present smooth muscle hypertrophy
and this change of morphology has an effect on urinary fre-
quency [8]. A direct link between ICB and detrusor hypertro-
phy has not been documented. However, it can be
hypothesised that ICB pathophysiologymight share some bio-
chemical cascades.
Clinical Scenarios
The ICB is a morphologic feature that can be presented in
some stages of multiple urological conditions. Radiological
characteristics include a reduced volumetric capacity, bladder
wall thickening with or without associated vesicoureteral re-
flux. Cystoscopic findings (when possible to execute due to
poor capacity) may differ, but mostly is a disturbed mucosa in
the form of erythema, ulcers, petechial, haemorrhage, and
trabeculations [2]. Table 1 summarises all the clinical scenar-
ios in which the ICB can be recognised.
Diagnosis and Investigations
Basic foundation for subsequent evaluation can be obtained
from medical history and physical examination. Factors such
as medication use, specific past medical history such as tuber-
culosis, ketamine abuse or pelvic radiotherapy must also be
factored into the decision and diagnostic paradigm [9]. Certain
physical examination factors must also be evaluated such as
enlarged prostate gland, hydronephrosis or any associated
neurologic abnormalities.
Both men and women with history of lower urinary tract
symptoms will require urinalysis [10]. Assessment modal-
ities include estimation of bladder capacity, post void re-
sidual assessment, cystoscopy, radiographic techniques
such as ultrasound of the urinary tract, CT urogram,
voiding cystourethrogram (VCUG) and MRI of the bladder
outlet and urethra can be performed. Further attempts at
refining the diagnosis of ICB may require urodynamic as-
sessment [9, 11].
Bladder capacity can be determined either from the maxi-
mum amount voided on the bladder diary, with non-invasive
uroflow study or during urodynamics. Men and women re-
quire a quality of life questionnaire such as the ICIQ-LUTS
questionnaire. Men [10] can also fill the International Prostate
Symptom Score (IPSS) questionnaire, have a digital rectal
examination and serum prostate-specific antigen (PSA) anal-
yses. In women [10], a pad test may be required if they
complained of urinary incontinence.
To confirm tuberculosis infection as the cause of ICB, it is
important to demonstrate mycobacterium in urine and radio-
graphic examination [12]. ‘Sterile pyuria’ is not very sensitive
or specific for urogenital tuberculosis, but persisting sterile
pyuria in an individual at risk should increase the index of
suspicion [13]. For the anatomical and functional details of
kidneys and ureters, intravenous urography (IVU) has been
considered to be one of the most useful tests. Pyelograms
disclosed abnormalities in 94% of cases [14]. Unfortunately,
pyelogram is useful only for late cavernous forms. If a patient
has renal failure, MRI of the urinary tract can be used [12]. It
may also be useful to perform provocation test with injection
of 20, 50 or 100 units of tuberculin subcutaneously [15].
Highly sensitive examinations such as radiometric liquid cul-
ture systems (i.e. BACTEC®, Becton Dickinson, USA) and
polymerase chain reaction (PCR) can also identify the myco-
bacterium [12].
Schistosomiasis, also known as bilharzia, is a common
intravascular infection caused by the parasitic Schistosoma
trematode worms which can predispose to ICB [16, 17].
‘Sandy patches’which are areas of roughened bladder mucosa
surrounding egg deposits are identified on cystoscopy exam-
ination. The trematode worm eggs are released in urine and
are detected by microscopy in a urine sample. In cases where
no egg is detectable in the urine, biopsy of the bladder may be
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considered for diagnosis in patients with a typical clinical
presentation of schistosomiasis.
ICB caused by inflammatory conditions will require a cys-
toscopy and bladder biopsy. Whereas ICB caused by drugs,
medications and radiation cystitis can be determined during
history taking. Urinalysis and urine culture in this group of
ICB, typically show sterile urine and occasionally, sterile py-
uria [18]. They will also complain of frequent voiding which
indicate small bladder capacity. Therefore, a bladder diary
should ideally be kept [19]. Radiographic investigations of
the upper urinary tract may reveal unilateral or bilateral
hydronephrosis (Fig. 1), circumferential mural thickening
with a small bladder capacity (Fig. 2) [19]. Small bladder
capacity (usually < 150 mL) with decreased bladder compli-
ance associated with detrusor overactivity will be apparent on
video urodynamic [20, 21] (Fig. 3).
Bladder Outlet Obstruction
Patients with bladder outflow obstruction mostly because of
benign prostatic obstruction (BPO) could present with
detrusor hypertrophy, obstruction induced detrusor overactiv-
ity and alterations in detrusor contractility. BPO produces a
structural damage on the bladder wall; this process could have
several stages. Commencing with a compensated phase, in
which the bladder counteracts the obstruction with a relatively
constant bladder mass and detrusor contraction, the end stage
or decompensation is characterised by a thick fibrous wall
with a low volumetric capacity and poor compliance. At this
stage, detrusor contraction is practically absent [9]. All of
these characteristics describe the ICB; therefore, its treatment
should be focused in managing bladder outflow obstruction at
an early stage.
Congenital Obstructed Bladder
Bladders that are defunctionalized early in life because of
congenital obstruction like posterior urethral valves, result in
Fig. 1 CT urography image shows bilateral gross hydronephrosis with
congenital pelvic right kidney
Table 1 Clinical scenarios of the
ICB Clinical scenarios Features that meet the criteria of ICB
Bladder outlet obstruction Decompensation stage
Congenital obstructed bladder Delayed treatment
Neurogenic bladder Deferred stages (e.g. spinal shock)
Infections When source and type of infection compromises
the bladder, especially in advanced diseaseTuberculosis
Schistosomiasis
Inflammatory conditions With positive cystoscopy and histology
Multifocal presentation
Fibrotic stage
Interstitial cystitis
Malacoplakia
Eosinophilic cystitis
Drugs and medications ICB as part of natural history of Ketamine bladder syndrome
Toxicity from chemotherapy or immunotherapy is rare presentation,
evidence mostly presented as side effect and based on case reports
Ketamine
Bacillus Calmette-Guérin (BCG)
Mitomycin C
Epirubicin
Gefitinib
Radiation cystitis Associated with high dose of radiation
Indwelling catheter When used for more than 6–12 months on free drainage
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reduced bladder capacity and never resume their function. The
hypertonicity and irritability are greater in the congenital
obstructed bladder when compared with the acquired obstruc-
tion [22]. Early intervention or obstruction repair in infants
with congenital obstructive lesions avoids the complications
of a contracted bladder later in life.
Neurogenic Bladder
The bladder can be altered differently in distinctive neurolog-
ical conditions and at different stages. Several molecular path-
ways have been postulated in the development of neurogenic
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Fig. 3 Video urodynamic study (pressure flow against time plot) shows small bladder capacity (< 50 mL), with associated detrusor overactivity
Fig. 2 CT urography image shows a small shrunken bladder with diffuse
wall thickening
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detrusor overactivity, detrusor underactivity and detrusor
sphincter dyssynergia. Neurogenic bladders present altered
tissue composition including an ICB [23]. Management for
these conditions should be based on mechanisms to empty
the bladder and protect the upper tract.
Infections
Tuberculosis
Tuberculosis (TB) is an infection caused by Mycobacterium
tuberculosis; genitourinary affection is the second most com-
mon form of extrapulmonary TB following the lymph nodes.
WhenMycobacterium tuberculosis affects the urinary tract, it
usually begins in the kidneys. Descending infection to the
bladder usually spreads through the ureteral orifices and lym-
phatics. Bacilli cause ulcerations in the urothelium producing
mucosal inflammation, haematuria and friability. It has been
postulated that after a year of chronic inflammation produced
by TB, the mucosal scarring leads to bladder contracture with
affectation of the upper tract and possibly urethral involve-
ment [24]. Urinary diversion and bladder augmentation are
treatment options for this form of IBC.
Schistosomiasis
This is a parasitic urinary tract infection caused by
Schistosoma haematobium; these flatworms are released from
snails and spread in water, then penetrate the human skin and
develop in the lungs and liver. Once mature, these adult
worms deposit their eggs in the bladder wall vessels and pro-
duce a granulomatous response provoking chronic inflamma-
tory response and fibrosis. This form of ICB is a risk factor for
squamous carcinoma of the bladder. Treatment options in-
clude praziquantel, but this antihelminthic has no effect on
the morphologic changes of the bladder wall [25].
Inflammatory Conditions
Interstitial Cystitis
Although the taxonomy of this entity is generally described as
bladder pain syndrome, some phenotypes present structural
changes in the bladder wall that are compatible with the
ICB. Traditionally, interstitial cystitis (IC) is described with
Hunner lesions, small mucosa vessels radiating towards a cen-
tral scar and/or the presence of glomerulations seen after
hydrodistention. IC is associated with a reduced bladder ca-
pacity and it shares some of the pathophysiology pathways of
the ICB [26, 27].
Malacoplakia
Malacoplakia is an inflammatory condition in which host de-
fences and phagocytosis are altered. It affects several organs
such as lungs, skin, mesenteric lymph nodes and gastrointes-
tinal and urinary tracts. Malacoplakia is characterised by soft,
yellow-brown plaques associated with Escherichia coli infec-
tions. A granulomatous reaction is produced containing his-
tiocytes also known asMichaelis-Gutmann bodies [28].When
it affects the urinary tract, this condition can progress to ICB,
especially when present with multifocal lesions [25]. The pro-
gression of this disease is associated with substantial morbid-
ity and a mortality of more than 50%.
Treatment of malacoplakia is mostly medical. In view of the
fact that malacoplakia is a rare condition, no widely medical
treatment guidelines have been established. Associated urinary
tract infections can be treated with antibiotic [29] that are effec-
tive at intracellular level such as quinolones (mainstay of treat-
ment), trimethoprim and rifampicin. These antibiotics are able
to aid the defective phagolysosomal mechanism found in
malakoplakia. These can be used long-term at low doses to
prevent recurrence. Sometimes in advance malacoplakia, surgi-
cal intervention maybe indicated [28, 30]. Operative procedure
depends on the organ(s) affected. In cases where the lesion is
causing obstruction to the ureters, transurethral resection can be
beneficial. Nephrostomy or ureteric stenting may also be con-
sidered. In advanced disease which involves extensive pelvic
malacoplakia, complex abdominal surgery which may involve
bladder and bowel resection may be necessary especially if the
bowel is involved.
Eosinophilic Cystitis
This inflammatory bladder condition is rare and is represented
by fibrosis and inflammation in the bladder with or without
muscle necrosis. This inflammation is postulated to be caused
by antigen-antibody complexes which attract eosinophils to
the bladder wall. This results in activation of enzymes and
cytokines that triggers the development of the ICB [25].
Several aetiological factors have been documented for eosin-
ophilic cystitis such as recurrent urinary tract infections, par-
asites, urinary tract surgeries, transitional cell carcinoma,
chronic granulomatous disease, eosinophilic enteritis, ovarian
teratoma, mitomycin C, tranilast [31–33] (also known as
Rizaben, is an antioxidant, antiallergic, antiangiogenesis and
anti-inflammatory agent that is used to treat disorders ranging
from bronchial asthma, keloids and oligozoospermia), and
some foods such as tomatoes, carrots and coffee [34]. This
condition could be self-limited; initial management consist
of non-steroidal anti-inflammatory drugs (NSAIDs), anti-his-
tamines, corticosteroids and cyclosporine. Cystectomy can be
a treatment option when eosinophilic cystitis reaches the point
of the ICB with hydronephrosis [34].
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Drugs and Medications
Ketamine
The recreational use of ketamine, an anaesthetic agent that is
often prescribed for chronic pain management [35], has been
associated with lower urinary tract symptoms with a preva-
lence of 20–90% among users. This drug causes cystitis with
haematuria and a contracted bladder with a significantly re-
duced bladder capacity [36]. The cystoscopic findings include
epithelial inflammation in the form of ulcerations, neovascu-
larization, denudation and petechia. There is no single defin-
itive management; various therapies have been proposed such
as antibiotics, NSAIDs, steroids, pentosan polysulphate, anti-
cholinergics, hydrodistension and bladder instillations with
hyaluronic acid or urinary diversion.
Bacillus Calmette-Guérin, Mitomycin C and Epirubicin
The use of intravesical agents as adjuvant treatments for non-
muscle-invasive bladder cancer have been related to reduced
bladder capacity and contracted bladder in less than 5% of
cases [37], mostly because of extravasation of intravesical
therapy. This is a serious complication and is associated with
multiple tumour resections and maintenance instillations.
Intravesical immunotherapy or chemotherapy must be
discontinued and a radical cystectomy should be considered
as part of treatment [38, 39].
Gefitinib
Gefitinib is an oral chemotherapy that inhibits the epidermal
growth factor receptor (EGFR) tyrosine kinase and is mostly
used as part of the treatment for non-small-cell lung cancer.
Some of the side effects of this medication include diarrhoea
and skin rash; however, haemorrhagic cystitis and the devel-
opment of ICB have been documented [40]. When patients on
this therapy present with urinary symptoms, gefitinib should
be halted.
Radiation Cystitis
Animal models have demonstrated that radiation to the blad-
der reduces cystometric capacity and compliance therefore
causing bladder dysfunction. These models have failed to ex-
plain historical findings of urothelial injury and fibrosis [41].
New pelvic radiotherapy techniques have reduced the toxicity
of this therapeutic modality; nonetheless, some side effects
compatible with the ICB have been documented [25, 42].
Chronic Use of Catheters
Several studies have suggested that use of indwelling catheters
on free drainage can contribute to a reduction of the bladder
capacity and function. After a period of 6–12 months, the
production of muscular fibrosis in the bladder wall leads to
structural changes that interfere with volumetric capacity and
compliance [43]. The use of valves in patients with indwelling
catheters gives the opportunity to mimic the healthy bladder
and has the potential to maintain, bladder capacity, tone and
function [44].
Discussion
In the same way that Krotoszyner stated that the ICB can be
related to several urological conditions, we suggest that some
pathologies can develop an ICB-like presentation.We theorise
that some pelvic tumours like muscle-invasive transitional cell
carcinoma or advance prostate cancer, urinary fistula and pa-
tients with multiple bladder surgeries can show some of the
morphologic features of the ICB. Krotoszyner presented a
case of a patient with sarcoma of the bladder and a case of
severe cystitis due to a bladder stone; both cases had ICB
characteristics [2].
Although the most common aetiologies of the ICB have
been presented in this article, other vesical pathologies can be
associated with some of the characteristics of the ICB. A
number of studies have suggested that ageing can lead to a
reduced cystometric capacity [10]. Elderly patients with
detrusor overactivity can present with a reduced bladder ca-
pacity as well [11]; however, these findings do not entirely
correspond with the morphology of the ICB.
Animal experimentations which induced metabolic syn-
drome have shown the presence of bladder alterations such
as hypoxia and fibrosis [45]; nonetheless, there is no evidence
of ICB in humans with metabolic syndrome.
End-stage kidney disease patients who present with
oliguria or anuria and are on dialysis can develop a reduced
cystometric capacity and compliance; a mean volume of
178 mL has been documented with the lowest range of
14 mL [46].
Certain connective tissue pathologies like systemic sclero-
sis or scleroderma have been associated with lower urinary
tract symptoms, urodynamic abnormalities and bladder wall
fibrosis [47]; however; the lowest volumetric capacity was
reported with 114 mL.
Conclusions
The inflammatory contracted bladder (ICB) can be found in a
wide spectrum of urological conditions. Moreover, some
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pathologies of the urinary tract can develop certain ICB mor-
phologic characteristics. Assessment and management should
be tailored according to the aetiology and stage of this vesical
entity.
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